公司已转至 OTC Pink 市场
, /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT)（&#34;Palatin&#34;或&#34;公司&#34;），是一家开发基于调节黑色素皮质素受体系统活性的分子的首创药物的生物制药公司，今天宣布完成了一项减少的、之前宣布的公开发行，参与者包括机构和合格投资者，共计 7,324,119 股普通股，以及可购买最多 7,324,119 股普通股的 F 系列认股权证（&#34; F 系列认股权证&#34;）、可购买最多 7,324,119 股普通股的 G 系列认股权证（&#34; G 系列认股权证&#34;）和可购买最多 7,324,119 股普通股的 H 系列认股权证（&#34; H 系列认股权证&#34;），以每股普通股及附带认股权证的联合公开发行价格为 0.15 美元（&#34; 发行&#34;）。
<img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/464561/Palatin_Technologies_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/464561/Palatin_Technologies_Logo.jpg"/>
F 系列认股权证的行使价格为每股 0.30 美元，立即可行使，并在原始发行日期五周年时到期，受某些条款的限制。G 系列认股权证的行使价格为每股 0.15 美元，立即可行使，并在以下两者中较早者到期：（i）原始发行日期的 24 个月周年纪念日或（ii）FDA 行使期的到期（该术语在 G 系列认股权证中定义）。H 系列认股权证将在持有人行使 G 系列认股权证时发行，行使价格为每股 0.225 美元，发行后立即可行使，并将在其发行日期的 24 个月周年纪念日到期。
公司从此次发行中获得的总毛收益约为 110 万美元。公司打算将此次发行的净收益主要用于营运资金和一般企业用途。
A.G.P./Alliance Global Partners 担任此次发行的主要配售代理，Laidlaw &amp; Company (UK) Ltd.担任此次发行的共同配售代理。
上述证券是根据修订后的 S-1 表格注册声明（文件编号 333-286280）提供的，该注册声明于 2025 年 5 月 6 日被证券交易委员会（&#34;SEC&#34;）宣布生效。此次发行仅通过构成有效注册声明的一部分的招股说明书进行。最终招股说明书的电子副本已提交给 SEC，并可在 SEC 的网站 http://www.sec.gov 上获取，也可以通过联系 A.G.P./Alliance Global Partners，地址为 590 Madison Avenue, 28th Floor, New York, NY 10022，电话 (212) 624-2060 或电子邮件 prospectus@allianceg.com 获取。
本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他管辖区进行这些证券的销售，除非在该州或其他管辖区的证券法下注册或合格之前，这种要约、邀请或销售是非法的。
关于 Palatin Palatin 是一家开发基于调节黑色素皮质素受体系统活性的分子的首创药物的生物制药公司，针对具有显著未满足医疗需求和商业潜力的疾病，提供靶向、受体特异性的产品候选者。Palatin 的战略是开发产品，然后与行业领导者形成市场合作，以最大化其商业潜力。有关 Palatin 的更多信息，请访问 Palatin 的网站 www.Palatin.com，并在 Twitter 上关注 Palatin，账号为 @PalatinTech。
前瞻性声明 本新闻稿中不属于历史事实的声明，包括与可能永远不会发生的与里程碑相关的 G 系列认股权证的潜在行使有关的声明，可能为公司带来额外的 110 万美元毛收益，发行收益的预期用途，均为《1933 年证券法》第 27A 条、《1934 年证券交易法》第 21E 条及《1995 年私人证券诉讼改革法》定义的&#34;前瞻性声明&#34;。Palatin 希望这些前瞻性声明受到所创造的安全港的保护。前瞻性声明反映了公司对未来事件的当前看法，并基于假设，受已知和未知的风险和不确定性影响，这些风险和不确定性会随时间变化，以及可能导致公司实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就存在重大差异的其他因素。这些因素包括但不限于市场和其他条件；发行收益的预期用途；临床试验的结果；FDA 及其他监管机构的监管行动及对监管批准的需求；Palatin 资助其技术开发和建立并成功完成临床试验的能力；完成临床试验和提交监管批准申请所需的时间和成本；竞争制药、生物制药和生物技术公司的产品；Palatin 产品的商业接受度；以及 Palatin 在 SEC 的定期文件中讨论的其他因素。本新闻稿中包含的所有前瞻性声明仅在本新闻稿日期有效。公司不承担更新任何书面或口头前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，除非法律要求。
Palatin Technologies®是 Palatin Technologies, Inc.的注册商标。
来源：Palatin Technologies, Inc.

PTNT

Palatin技术

PTNTD

Palatin Technologies, Inc. 宣布完成了一项缩减的公开发行，通过出售 7,324,119 股普通股及相关的 F、G 和 H 系列认股权证筹集了约 110 万美元。此次发行是以每股 0.15 美元的价格向机构和合格投资者进行的。筹集的资金将用于营运资金和一般企业用途。A.G.P./Alliance Global Partners 担任主承销商。该公司专注于开发针对黑色素皮质激素受体系统的一流生物制药

Company Transitioned onto the OTC Pink
<div class="lb-trans">公司已转至 OTC Pink 市场
</div>, /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) (&#34;Palatin&#34; or the &#34;Company&#34;), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the &#34; Series F Warrants&#34;), Series G warrants to purchase up to 7,324,119 shares of common stock (the &#34; Series G Warrants&#34;), and Series H warrants to purchase up to 7,324,119 shares of common stock (the &#34; Series H Warrants&#34;), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the &#34; Offering&#34;).
<div class="lb-trans">, /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT)（&#34;Palatin&#34;或&#34;公司&#34;），是一家开发基于调节黑色素皮质素受体系统活性的分子的首创药物的生物制药公司，今天宣布完成了一项减少的、之前宣布的公开发行，参与者包括机构和合格投资者，共计 7,324,119 股普通股，以及可购买最多 7,324,119 股普通股的 F 系列认股权证（&#34; F 系列认股权证&#34;）、可购买最多 7,324,119 股普通股的 G 系列认股权证（&#34; G 系列认股权证&#34;）和可购买最多 7,324,119 股普通股的 H 系列认股权证（&#34; H 系列认股权证&#34;），以每股普通股及附带认股权证的联合公开发行价格为 0.15 美元（&#34; 发行&#34;）。
</div><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/464561/Palatin_Technologies_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/464561/Palatin_Technologies_Logo.jpg"/>
The Series F Warrants have an exercise price of $0.30 per share, are immediately exercisable and expire on the five-year anniversary of the original issuance date, subject to the certain terms as defined in such warrant. The Series G Warrants have an exercise price of $0.15 per share, are immediately exercisable and expire on the earlier of (i) the 24-month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period (as such term is defined in the Series G Warrant). The Series H Warrants will be issuable to the holder upon their exercise of the Series G Warrants, will have an exercise price of $0.225 per share, will be immediately exercisable upon issuance and will expire on the 24-month anniversary of its issuance date.
<div class="lb-trans">F 系列认股权证的行使价格为每股 0.30 美元，立即可行使，并在原始发行日期五周年时到期，受某些条款的限制。G 系列认股权证的行使价格为每股 0.15 美元，立即可行使，并在以下两者中较早者到期：（i）原始发行日期的 24 个月周年纪念日或（ii）FDA 行使期的到期（该术语在 G 系列认股权证中定义）。H 系列认股权证将在持有人行使 G 系列认股权证时发行，行使价格为每股 0.225 美元，发行后立即可行使，并将在其发行日期的 24 个月周年纪念日到期。
</div>The Company received aggregate gross proceeds from the Offering of approximately $1.1 million. The Company intends to use the net proceeds from the Offering primarily for working capital and general corporate purposes.
<div class="lb-trans">公司从此次发行中获得的总毛收益约为 110 万美元。公司打算将此次发行的净收益主要用于营运资金和一般企业用途。
</div>A.G.P./Alliance Global Partners acted as lead placement agent for the Offering and Laidlaw &amp; Company (UK) Ltd. acted as co-placement agent for the Offering.
<div class="lb-trans">A.G.P./Alliance Global Partners 担任此次发行的主要配售代理，Laidlaw &amp; Company (UK) Ltd.担任此次发行的共同配售代理。
</div>The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-286280), relating to the Offering which was declared effective by the Securities and Exchange Commission (the &#34;SEC&#34;) on May 6, 2025. The Offering was made only by means of a prospectus forming part of the effective registration statement relating to the Offering. An electronic copy of the final prospectus was filed with the SEC and may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting A.G.P./Alliance Global Partners at 590 Madison Avenue, 28th Floor, New York, NY 10022, by phone at (212) 624-2060 or e-mail at prospectus@allianceg.com.
<div class="lb-trans">上述证券是根据修订后的 S-1 表格注册声明（文件编号 333-286280）提供的，该注册声明于 2025 年 5 月 6 日被证券交易委员会（&#34;SEC&#34;）宣布生效。此次发行仅通过构成有效注册声明的一部分的招股说明书进行。最终招股说明书的电子副本已提交给 SEC，并可在 SEC 的网站 http://www.sec.gov 上获取，也可以通过联系 A.G.P./Alliance Global Partners，地址为 590 Madison Avenue, 28th Floor, New York, NY 10022，电话 (212) 624-2060 或电子邮件 prospectus@allianceg.com 获取。
</div>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
<div class="lb-trans">本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他管辖区进行这些证券的销售，除非在该州或其他管辖区的证券法下注册或合格之前，这种要约、邀请或销售是非法的。
</div>About Palatin Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
<div class="lb-trans">关于 Palatin Palatin 是一家开发基于调节黑色素皮质素受体系统活性的分子的首创药物的生物制药公司，针对具有显著未满足医疗需求和商业潜力的疾病，提供靶向、受体特异性的产品候选者。Palatin 的战略是开发产品，然后与行业领导者形成市场合作，以最大化其商业潜力。有关 Palatin 的更多信息，请访问 Palatin 的网站 www.Palatin.com，并在 Twitter 上关注 Palatin，账号为 @PalatinTech。
</div>Forward Looking Statements Statements in this press release that are not historical facts, including the potential exercise of the milestone related Series G Warrants, which may never occur, for additional gross proceeds to the Company of $1.1 million, the intended use of proceeds from the Offering, are &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements reflect the Company's current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, without limitation, market and other conditions; the anticipated use of proceeds from the Offering; results of clinical trials; regulatory actions by the FDA and other regulatory and the need for regulatory approvals; Palatin's ability to fund development of its technology and establish and successfully complete clinical trials; the length of time and cost required to complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin's products; and other factors discussed in Palatin's periodic filings with the SEC. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
<div class="lb-trans">前瞻性声明 本新闻稿中不属于历史事实的声明，包括与可能永远不会发生的与里程碑相关的 G 系列认股权证的潜在行使有关的声明，可能为公司带来额外的 110 万美元毛收益，发行收益的预期用途，均为《1933 年证券法》第 27A 条、《1934 年证券交易法》第 21E 条及《1995 年私人证券诉讼改革法》定义的&#34;前瞻性声明&#34;。Palatin 希望这些前瞻性声明受到所创造的安全港的保护。前瞻性声明反映了公司对未来事件的当前看法，并基于假设，受已知和未知的风险和不确定性影响，这些风险和不确定性会随时间变化，以及可能导致公司实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就存在重大差异的其他因素。这些因素包括但不限于市场和其他条件；发行收益的预期用途；临床试验的结果；FDA 及其他监管机构的监管行动及对监管批准的需求；Palatin 资助其技术开发和建立并成功完成临床试验的能力；完成临床试验和提交监管批准申请所需的时间和成本；竞争制药、生物制药和生物技术公司的产品；Palatin 产品的商业接受度；以及 Palatin 在 SEC 的定期文件中讨论的其他因素。本新闻稿中包含的所有前瞻性声明仅在本新闻稿日期有效。公司不承担更新任何书面或口头前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，除非法律要求。
</div>Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.
<div class="lb-trans">Palatin Technologies®是 Palatin Technologies, Inc.的注册商标。
</div>SOURCE Palatin Technologies, Inc.
<div class="lb-trans">来源：Palatin Technologies, Inc.
</div>

Palatin Tech 宣布完成缩减后的公开发行 | PTN 股票新闻